

Edgar Filing: VistaGen Therapeutics, Inc. - Form 8-K

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Item 7.01

Regulation FD Disclosure

See Item 8.01 below.

Item 8.01

Other Events.

On January 3, 2018, VistaGen Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track Designation to AV-101, the Company’s lead central nervous system product candidate for development as a potential adjunctive treatment for Major Depressive Disorder. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.

On January 8, 2018, the Company began utilizing a new corporate presentation (the “Corporate Presentation”). A copy of the Corporate Presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K, and is incorporated by reference herein.

In addition, the Company will be presenting at the 10th Annual Biotech Showcase Conference in San Francisco, California on Monday, January 8, 2018 at 4:00 P.M. Pacific Time.

The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

See Exhibit Index.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VistaGen Therapeutics, Inc.

Date: January 8, 2018 By: /s/ Shawn K. Singh
Shawn K. Singh
Chief Executive Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release issued by VistaGen Therapeutics, Inc., dated January 3, 2018
99.2 Corporate Presentation, dated January 2018